BACKGROUND: Streptokinase resistance may cause suboptimal thrombolytic therapy. AIM: To develop a rapid latex-bead assay to detect streptokinase antibodies. METHODS: Sera were obtained from 16 patients presenting with acute myocardial infarction (MI) before treatment with streptokinase and 1 and 6 months post treatment, and from 100 controls. Sera were assayed for anti-streptokinase antibodies using a functional streptokinase-neutralising assay. RESULTS: Streptokinase-neutralising activity was low in controls (54 +/- 5U/ml) and patients prior to treatment (101 +/- 18), increasing to 2,110 +/- 823 and 1,017 +/- 169 at 1 and 6 months (mean +/- SEM). The latex assay had a sensitivity of 94% and a specificity of 93% for detecting individuals with > 350U/ml of streptokinase resistance, which is sufficient to neutralise the drug clinically. CONCLUSIONS: Estimation of streptokinase resistance using an enzyme immunoassay and a latex bead assay correlated well with serum neutralising activity. This assay can rapidly identify patients who have a high level of streptokinase-neutralising activity.
BACKGROUND: Streptokinase resistance may cause suboptimal thrombolytic therapy. AIM: To develop a rapid latex-bead assay to detect streptokinase antibodies. METHODS: Sera were obtained from 16 patients presenting with acute myocardial infarction (MI) before treatment with streptokinase and 1 and 6 months post treatment, and from 100 controls. Sera were assayed for anti-streptokinase antibodies using a functional streptokinase-neutralising assay. RESULTS: Streptokinase-neutralising activity was low in controls (54 +/- 5U/ml) and patients prior to treatment (101 +/- 18), increasing to 2,110 +/- 823 and 1,017 +/- 169 at 1 and 6 months (mean +/- SEM). The latex assay had a sensitivity of 94% and a specificity of 93% for detecting individuals with > 350U/ml of streptokinase resistance, which is sufficient to neutralise the drug clinically. CONCLUSIONS: Estimation of streptokinase resistance using an enzyme immunoassay and a latex bead assay correlated well with serum neutralising activity. This assay can rapidly identify patients who have a high level of streptokinase-neutralising activity.
Authors: J D Gemmill; K J Hogg; J M Burns; A P Rae; F G Dunn; R Fears; H Ferres; R Standring; H Greenwood; D Pierce Journal: Br J Clin Pharmacol Date: 1991-02 Impact factor: 4.335
Authors: M B Buchalter; G Suntharalingam; I Jennings; C Hart; R J Luddington; R Chakraverty; S K Jacobson; P L Weissberg; T P Baglin Journal: Br Heart J Date: 1992-11